A Proposed Federal Rule Could Reshape Medicine in Washington, DC June 18, 2026

Cross posted from the MSDC Substack

A sweeping proposed federal regulation quietly published on May 29, 2026, could fundamentally alter how physicians in Washington, DC practice, teach, and conduct research. If you receive, administer, or benefit from federal grant funding — or if your patients do — this rule affects you.

The public comment deadline is July 13, 2026.
---

What Is This Rule?

The Office of Management and Budget (OMB) has proposed a major revision to the “Uniform Guidance,” the regulatory framework that governs all federal financial assistance — including research grants from NIH, NSF, CDC, the Department of Defense, and virtually every other federal agency. The proposal, formally titled *Regulation for Federal Financial Assistance* (Docket OMB-2026-0034), was published by OMB alongside more than 40 federal agencies.

What makes this revision different from past updates is its scope and intent. For the first time, the Uniform Guidance would be converted from non-binding guidance into legally enforceable federal regulation, effective October 1, 2026 — a compressed timeline that experts across medicine, science, and law have called alarming. The Association of American Medical Colleges (AAMC) has flagged the rule as a significant threat to research universities, academic medical centers, and the broader biomedical enterprise.

---
How This Affects DC Physicians: Three Critical Threats

1. Political Appointees Would Take Over Grant Funding Decisions

For generations, the question of which medical research gets funded has been answered by scientific peer review. Panels of expert scientists evaluate proposals, score them rigorously, and only the most meritorious — often the top 3 to 20 percent — receive NIH or other federal funding. 

Under this proposed rule, senior political appointees would be required to conduct a “pre-issuance review” of every discretionary grant before it is awarded — and they would be explicitly forbidden from simply deferring to peer reviewers. The criteria they must apply would include blocking awards related to “gender ideology,” anything deemed to “promote anti-American values,” or research that does not “demonstrably advance the President’s policy priorities.”

For DC’s physician-researchers at GW, Georgetown, Howard, MedStar, Children’s National, and the NIH campus itself, this means that decades of carefully built research programs could become politically vulnerable overnight. A cancer immunology study, a health disparities investigation, or a clinical trial addressing adolescent mental health could be defunded not because the science is weak, but because it is politically inconvenient.

2. Ongoing Research Grants Could Be Canceled Mid-Study — Without Warning

Under current rules, a federally funded multi-year research grant carries an expectation that the government will honor its commitment for the duration of the award. Under this proposed rule, grants could be terminated at any point, at the government’s sole discretion, with no legal obligation to complete the funded period.

This is not a hypothetical inconvenience. For a DC teaching physician running a five-year NIH clinical trial, termination at year three means:

- Research staff, postdoctoral fellows, and graduate students lose their jobs
- Patients enrolled in the trial may lose access to experimental treatments or follow-up care
- Years of collected data may be rendered unpublishable or unusable
- Millions of taxpayer dollars already invested produce no return

Science is not a subscription service. You cannot pause a longitudinal patient study the way you pause a magazine. When the funding stops, the science stops — and the potential breakthroughs stop with it.

3. Communicating Research Findings Would Become Harder and More Restricted

The proposed rule contains provisions that would prohibit the use of federal funds for journal publication costs — including open-access fees that allow the public to read the research their tax dollars funded. It would also restrict scientists from attending conferences unless those conferences were pre-approved at the time the grant was originally awarded, disadvantaging newer or politically disfavored professional meetings. And it would limit researchers’ ability to publicly discuss how their findings should inform policy or public health guidelines.

For the DC medical community — where physician-researchers regularly translate findings into clinical guidance, testify before Congress, and engage with federal health agencies — these restrictions would sever the critical link between discovery and practice. As one expert has noted, science is not finished until it is communicated. 
---
What’s at Stake for DC’s Medical Community Specifically

The proposed rule, if finalized as written, would:

• Chill research on health disparities and minority health — topics of profound importance in a DC — because such work could be flagged under proposed prohibitions on DEI-related research
• Destabilize the training pipeline, as junior faculty and trainees abandon careers that no longer offer stable funding prospects
• Damage DC’s competitive position as a research hub, as scientists seek positions in countries with more stable research environments
• Harm patients, who depend on clinical trials and translational research for access to cutting-edge treatments

The damage may outlast any single administration. Once research teams are disbanded and scientists leave the field or the country, that expertise does not return on a political timeline.
---

What DC Physicians Can Do — Before July 13

The good news: this rule is not final. Under the Administrative Procedure Act, OMB is legally required to accept and respond to substantive public comments before issuing a final rule. Those comments create a formal record that informs Congress, supports potential litigation, and can compel meaningful changes to the rule before it takes effect.

Here is how to act:

Submit a Public Comment (Most Important — Deadline: July 13, 2026)

Go here and click “Comment.” Comments must be individual and in your own words — identical submissions count only once.

Effective comments:

• Describe who you are and your connection to federally funded medicine (researcher, clinician, educator, trainee)
• Share a specific, personal story about how federal funding has shaped your work or your patients’ care — a cancer survivor you treated, a drug you prescribe that came from NIH-funded work, a clinical trial that changed a patient’s prognosis
• Explain concretely which provisions concern you most and why (see sections §200.205 on merit review, §200.340 on termination, §200.461 on publication costs)
• State clearly that you oppose the rule as written and ask OMB to withdraw or substantially revise it

Your comment, including your name, will be posted publicly.

Engage Through MSDC and Your Institution

Many DC academic institutions — including GW and Georgetown — are coordinating institutional responses through national partners including the AAMC, the Association of American Universities (AAU), and the Council on Governmental Relations (COGR). Contact your institution’s Office of Research or Vice Provost for Research to learn how to contribute to a coordinated response.

MSDC is monitoring this rule closely and will continue to provide updates. Members who would like to coordinate advocacy efforts are encouraged to reach out directly.

Share This Information

The impact of this rule extends far beyond the research community. Patients, families, and community members who have benefited from federally funded medicine — which is essentially everyone — have standing to comment. Help us reach them.

---
Bottom Line

The proposed OMB rule is one of the most consequential changes to the federal research enterprise in decades. It would convert the independence of American medical science into a politically managed system, and it would do so on a timeline — October 1, 2026 — that gives the research community almost no time to adapt.


*For questions or to coordinate advocacy, contact the Medical Society of the District of Columbia at hay@msdc.org.